Gemcitabine (GEM) + oxaliplatin (OX) in patients (pts) with stage III/IV ovarian cancer following 3 cycles of carboplatin (CB) + paclitaxel (PAC): Preliminary report of a phase II study

Arca, Roberta; Ibarra, Jorge E.; Lerzo, Guillermo; Mandachain, Mariano; Mickievicz, E.; Pérez, Josué; Richardet, Eduardo; Rodger, J.; Kooten, Maximiliano Van; Orlando, Mauro

doi:10.1200/jco.2004.22.90140.5111

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gemcitabine 1000 mg/m 2 on day 1 followed by oxaliplatin 85 mg/m 2 on day 2 were administered once every 2 weeks (48) . Of 13 patients evaluable for CA125 response, 12 had CR and 1 had disease progression.…”

Section: Oxaliplatin Plus Gemcitabinementioning

confidence: 99%

Clinical application of oxaliplatin in epithelial ovarian cancer

Fu¹,

Kavanagh²,

Hu³

et al. 2006

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

Platinum remains the most active drug class in ovarian cancer treatment; however, new single-agent and combination therapies are needed to improve the clinical outcome of ovarian cancer therapies. Oxaliplatin, a third-generation platinum derivative, has shown effective antitumor activity and a favorable toxicity profile in epithelial ovarian cancer. Preclinical evidence of the synergistic cytotoxic effect of oxaliplatin in combination with several other chemotherapeutic agents and clinical evidence of the absence of any dose-limiting hematologic toxicity associated with this agent have made oxaliplatin an attractive compound for combination agent therapy. This article reviews the current status of the clinical application of oxaliplatin alone and in a combination regimen in epithelial ovarian cancer treatment.

show abstract

Section: Oxaliplatin Plus Gemcitabinementioning

confidence: 99%

Clinical application of oxaliplatin in epithelial ovarian cancer

Fu¹,

Kavanagh²,

Hu³

et al. 2006

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

show abstract

Gemcitabine and oxaliplatin followed by paclitaxel and carboplatin as first line therapy for patients with suboptimally debulked, advanced epithelial ovarian cancer. A phase II trial of sequential doublets. The GO-First Study

Steer

Chrystal

Cheong

et al. 2006

Gynecologic Oncology

View full text Add to dashboard Cite

Intra-tumor heterogeneity for endometrial cancer and its clinical significance

Yin

Zhao

et al. 2019

Chinese Medical Journal

View full text Add to dashboard Cite

Background: Management of tumors has become more complex owing to tumor heterogeneity. Fewer studies have been performed on intra-tumor heterogeneity of endometrial cancer (EC) until now. Therefore, it is of great clinical value to explore the intra-tumor heterogeneity of EC based on clinical features and gene expression profiles. Methods: A total of 1688 patients with EC were screened and 114 patients were finally selected, including specimens from 84 patients with primary EC without relapse (PE) and the paired metastases (P-M) specimens, as well as specimens from 30 patients with primary EC with relapse (RPE) and the paired relapsed EC (P-RE) specimens. Microarray and RNA-seq were used to detect gene expression of EC samples. Clinicopathological characteristics and molecular data were compared between PE and P-M groups and between RPE and P-RE groups to explore the intra-tumor heterogeneity of EC. Results: The clinical intra-tumor spatial heterogeneity of pathological type, grade, ER status, and PR status between PE and P-M were 17.9%, 13.1%, 28.6%, and 28.6%, respectively. The clinical intra-tumor spatiotemporal heterogeneity of pathological type, grade, ER status, and PR status between RPE and P-RE were 16.7%, 33.3%, 25.0%, and 37.5%, respectively. Cluster analysis sorts EC samples based on progression type of lesion and their pathological type. There were differentially expressed genes between PE and P-M and between RPE and P-RE, of which gene ontology and Kyoto Encyclopedia of Genes and Genomes analysis were mainly enriched in cell proliferation, the p53 signaling pathway, etc. Conclusions: Clinical and molecular data showed that there was spatiotemporal heterogeneity in intra-tumor of EC, which may add to the complexity of diagnosis and therapeutics for EC. Considering the intra-tumor heterogeneity, sequential chemotherapy and precision medicine may be a more suitable treatment plan for EC.

show abstract

Gemcitabine (GEM) + oxaliplatin (OX) in patients (pts) with stage III/IV ovarian cancer following 3 cycles of carboplatin (CB) + paclitaxel (PAC): Preliminary report of a phase II study

Cited by 3 publications

References 0 publications

Clinical application of oxaliplatin in epithelial ovarian cancer

Clinical application of oxaliplatin in epithelial ovarian cancer

Gemcitabine and oxaliplatin followed by paclitaxel and carboplatin as first line therapy for patients with suboptimally debulked, advanced epithelial ovarian cancer. A phase II trial of sequential doublets. The GO-First Study

Intra-tumor heterogeneity for endometrial cancer and its clinical significance

Contact Info

Product

Resources

About